title: [Methotrexate treatment of rheumatoid arthritis in Denmark].
abstract: In the recommended early, aggressive and continuous treatment strategy of rheumatoid arthritis (RA), methotrexate (MTX) is the anchor drug, and although generally well tolerated approximately 50% of the RA patients discontinue MTX treatment within five years. In a large Danish cohort study among newly diagnosed patients with RA only 21% had started MTX treatment within 90 days after referral to hospital and the median time-to-treatment initiation was 120 days. Furthermore, MTX compliance is considered generally high among Danish RA patients and the patients have strong beliefs about MTX necessity.
authors: Forskningsenheden for sygepleje, Aarhus Universitetshospital, Aarhus Sygehus, Denmark. annethur@rm.dk
authors: Annette
authors: A
authors: de Thurah
authors: Mette
authors: M
authors: Nørgaard
authors: Kristian
authors: K
authors: Stengaard-Pedersen
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000000981:diagnostic imaging / Q000188:drug therapy*; D003718:Denmark; D006801:Humans; D055118:Medication Adherence; D008727:Methotrexate / Q000627:therapeutic use*; D011859:Radiography; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D008727:Methotrexate